Трудные вопросы диагностики и лечения синдрома раздраженного кишечника в педиатрической практике


Н.И. Урсова

ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского», Москва
Широкая распространенность, многочисленность и разнообразие причинных факторов, вариабельность клинических проявлений, сложность регистрации расстройств со стороны толстой кишки и ее сфинктерной системы поддерживают интерес интернистов к диагностике и лечению синдрома раздраженного кишечника. С учетом большого разнообразия признаков системности процесса в детском возрасте целесообразно комплексно обследовать больных с абдоминальной болью и диспепсическими явлениями. Принципиальное значение для педиатрической практики имеет точный синдромный диагноз, который определяет необходимость и стратегию лечения, при этом тактической задачей врача остается выбор препарата с наибольшим терапевтическим и наименьшим токсическим потенциалом.

Литература



  1. Saito Y.A., Shoenfeld P., Locke G.R.I. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am. J. Gastroenterol 2002;97:1910–15.

  2. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 2004;20(7):31–7.

  3. Gwee K.A. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol. Motil. 2005;17:317–24.

  4. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. 2011;140(3):761–65.

  5. Drossman D.A. The functional Gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377–90.

  6. Thompson W.G. The road to Rome Gastroenterology. 2006;130(5);1466–79.

  7. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.

  8. Dumitrascu D.L. Making a Positive Diagnosis of IBS. Pan-European Conference on Irritable Bowel Syndrom, Vienna, December 10th, 2010.

  9. Quigley E.M., Abdel–Hamid H., Barbara G., Bhatia S.J., Boeckxstaens G., De Giorgio R., Delvaux M., Drossman D.A., Foxx–Orenstein A.E., Guamer F., Gwee K.A., Harris L.A., Hungin A.P., Hunt R.H., Kellow J.E., Khalif I.L., Kruis W., Lindberg G., Olano C., Moraes–Filho J.P., Schiller L.R., Schmulson M., Simren M., Tzeuton C. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J. Clin. Gastroenterol. 2012;46(5):356–66.

  10. Simren M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–76.

  11. Ghoshal U.C., Ranjan P. Post–infectious irritable bowel syndrome: the past, the present and the future. J. Gastroenterol. Hepatol. 2011;3:94–101.

  12. DuPont A.W., DuPont H.L. The intestinal microbiota and chronic disorders of the gut. Nat. Rev. Gastroenterol. Hepatol. 2011;8(9):523–31.

  13. Posserud I., Stotzer P.O., Bjornsson E.S., Abrahamsson H., Simren M.. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–8.

  14. Halvorson H.A., Schlett C.D., Riddle M.S. Postinfectious irritable bowel syndrome-meta-analysis. Am. J. Gastroenterol. 2006;101:1894–99.

  15. Thabane M., Kottachchi D.T., Marshall J.K. Systematic review and meta-analysis. The incidence and prognosis of postinfections irritable bowel syndrome. Falk. Gastro. Rev. J. 2007.

  16. Урсова Н.И. Микробиоценоз открытых биологических систем организма в процессе адаптации к окружающей среде. РМЖ. Детская гастроэнтерология и нутрициология. 2004;12(16):957–59.

  17. Sykes M.A., Blanchard E.B., Lackner J., Keefer L., Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J. Behav. Med. 2003;26:361–72.

  18. Al–Chaer E., Feng Y., Willis W.D. Visceral Pain: A disturbance in the sensorimotor continuum? Pain Forum. 1998;3:117–25.

  19. Zeltzer L.K., Arnoult S., Hamilton A., DeLaura S. In: Pediatric Gastrointestinal Motility Disorders. Human P.E., eds. NY: Academy Professional Information Services; 1994. P. 155–76.

  20. Cervero F. Mechanisms of Visceral Pain; Past and Present. In: Visceral Pain: Progress in Pain Research and Management. Gebhart G.F., eds. Seattle, WA: IASP Press; 1995. P. 25–40.

  21. Devor M. Pain mechanism and pain syndromes. An Updated Review, IASP Press; 1996. P. 103–12.

  22. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N. Engl. J. Med. 2012;367(17):1626–35.

  23. Agrawal A., Houghton L.A., Lea R., Morris J., Reilly B., Whorwell P.J. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology. 2008;134:1882–89.

  24. Sperber A.D., Drossman D.A. Functional Abdominal Pain Syndrome. Am. J. Gastroenterol. 2010;105:770–75.

  25. Monnikes H. Quality of life in Irritable Bowel Syndrom. Pan-European Conference on Irritable Bowel Syndrom, Vienna, December 10th, 2010.

  26. Новиков А.В., Яхно Н.Н. Невропатическая боль, патофизиологические механизмы и принципы терапии. РМЖ. 2001;9(7–8):318–27.

  27. Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R. Activated mast cell in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;12:693–702.

  28. Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Bunnett N.W., Grundy D., Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.

  29. Крыжановский Г.Н. Дизрегуляционная патология. Руководство для врачей и биологов. М., 2002. 38 с.

  30. North C.S., Downs D., Clouse R.E., Alrakawi A., Dokucu M.E., Cox J., Spitznagel E.L., Alpers D.H. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin. Gastroenterol. Hepatol. 2004;2:787–95.

  31. Levy R.L., Olden K.W., Naliboff B.D., Bradley L.A., Francisconi C., Drossman D.A., Creed F. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006;130:1447–58.

  32. Irving G.A., Wallace M.S. Pain Management for the Practicing Physician. NY: Churchill Livingston; 1997.

  33. Camilleri M., Bueno L., de Ponti F., Fioramonti J., Lydiard R.B., Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1421–34.

  34. Boesmans W., Owsianik G., Tack J., Voets T., Vanden Berghe P. TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br. J. Pharmacol. 2011;162:18–37.

  35. Holzer P. TRP channels in the digestive system. Curr. Pharm. Biotechnol. 2011;12:24–34.

  36. Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923–9.

  37. Winston J., Shenoy M., Medley D., Naniwadekar A., Pasricha P.J. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007;132:615–27.

  38. Vriens J., Nilius B., Vennekens R. Herbal compounds and toxins modulationg TRP channels. Curr. Neuropharmacol. 2008;6:79–96.

  39. Spiller R., Lam C. An update on post-infectious Irritable Bowel Syndrome: Role of genetics, immune activation, serotonin and altered microbiome. J. Neurogastroenterol. Motil. 2012;18(3):258–68.

  40. Beutheu–Youmba S., Belmonte L.E., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coёffier M. The expression of the tight junction proteins, claudin-1, occluding and ZO-1 is redused in the colonic mucosa of patients with irritable bowel syndrome. Gut. 2010;59:52.

  41. Aerssens J., Camilleri M., Talloen W., Thielemans L., Göhlmann H.W., Van Den Wyngaert I., Thielemans T., De Hoogt R., Andrews C.N., Bharucha A.E., Carlson P.J., Busciglio I., Burton D.D., Smyrk T., Urrutia R., Coulie B. Alteration in mucosal immunity identied in the colon of patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2008;6:194–205.

  42. Saito Y.A., Mitra N., Mayer E.A. Genetic approaches to functional gastrointestinal disorders. Gastroenterolody. 2010;138(4):1276–85.

  43. Camilleri M. Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig. Dis. Sci. 2009;54(11):2318–24.

  44. Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2010;31(1):35–46.

  45. Martinez C., Vicario M., Lobo B., Pigrau M., Martinez C., Alonso C., Guila T., de Torres I., Azpiroz F., Santos J. Mucosal mast cell-mediated tight junction impairment correlates to symptom severity in diarrhea-prone irritable bowel syndrome patients. Gut. 2010;59:18.

  46. Mohammadian G., Dlugosz A., Lindberg G. Human β–defensins in colon mucosa of patients with irritable bowel syndrome, inflammatory bowel disease and healthy controls. Gut. 2011;60:313.

  47. Shepherd S.J., Parker F.C., Muir J.G., Gibson P.R. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin. Gastroenterol. Hepatol. 2008;6(7):765–71.

  48. Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75.

  49. Staudacher Y.M., Whelan K., Irving PM., Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J. Hum. Nutr. Diet. 2011;24(5):487–95.

  50. Murray K., Wilkinson–Smith V., Hoad C., Costigan C., Cox E., Lam C., Marciani L., Gowland P., Spiller R.C. Differential Effects of FODMAPs (Fermentable Oligo-, Di-, Monosaccharides and Polyols) on Small and Large Intestinal Contents in Healthy Subjects Shown by MRI. Am. J. Gastroenterol. 2014;109(1):110-9.

  51. Yang J., Fox M., Cong Y., Chu H., Zheng X., Long Y., Fried M., Dai N. Lactose intolerance in irritable bowel syndrome patients with diarrhea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity. Aliment. Pharmacol. Ther. 2014;39(3):302–11.

  52. Atkinson W., Sheldon T.A., Shaath N., Whorwell P.J. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut. 2004;53:1459–64.

  53. Nanda R., James R., Smith H., Dudley C.R., Jewell D.P. Food intolerance and the irritable bowel syndrome. Gut. 1989;30:1099–104.

  54. Verdu E.F. Can gluten contribute to irritable bowel syndrome? Am. J. Gastroenterol. 2011;106:516–18.

  55. Verdu E.F., Huang X., Natividad J., Lu J., Blennerhassett P.A., David C.S., McKay D.M., Murray J.A. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgene mice. Am. J. Physio-Gastrointest. Liv. Physiol. 2008;294:217–25.

  56. Ford A.C., Talley N.J., Spiegel B.M., Foxx-Orenstein A.E., Schiller L., Quigley E.M., Moayyedi P. Effect of fibre, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;13:337.

  57. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2001;15:355.

  58. Полуэктова Е.А., Кучумова С.Ю., Шептулин А.А., Ивашкин В.Т. Лечение синдрома раздраженного кишечника спозиций современных представлений о патогенезе заболевания. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013;23(1):57–65.

  59. Cann P.A., Read N.W., Holdsworth C.D., Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig. Dis. Sci. 1984;29(3):239–47.

  60. Efskind P.S., Bernklev T., Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand. J. Gastroenterol. 1996;31(5):463–8.

  61. Low K., Hwang L., Hua J., Zhu A., Morales W., Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on laclulose breath test. J. Clin. Gastroenterol. 2010;44(8):547–50.

  62. Pimentel M., Lembo A., Chey W.D., Zakko S., Ringel Y., Yu J., Mareya S.M., Shaw A.L., Bortey E., Forbes W.P. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 2011;364(1):22–32.

  63. DiPalma J.A., Cleveland M.V., McGowan J., Herrera J.L. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am. J. Gastroenterol. 2007;102:1436–41.

  64. Whelan K., Quigley E.M. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr. Opin. Gastroenterol. 2013;29(2):184–89.

  65. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx–Orenstein A.E., Brandt L.J., Quigley E.M. The efficacy of probiotics in the treatment of irritable bowel syndrome: asystematic review. Gut. 2010;59(3):325–32.


Об авторах / Для корреспонденции


Н.И. Урсова – д.м.н., проф., рук.педиатрической клиникой ГБУЗ МО МОНИКИ им. М.Ф. Владимирского, заведующая кафедрой педиатрии ФУВ МОНИКИ, главный педиатр МЗ МО; тел. 8 (495) 681-25-98


Похожие статьи


Бионика Медиа